Bafetinib (previously known as INNO-406) is a protein kinase inhibitor that targets two different enzymes. The newly announced trial is designed to investigate the potential of bafetinib in the treatment of men with castration-resistant prostate cancer (CRPC) who have progressive disease after treatment with at least one course of chemotherapy.
The Phase II PROstate Advanced Cancer Treatment (PROACT) trial is being conducted at the City of Hope cancer center, outside of Los Angeles, California, as well as in several centers in India. For details about this trial and more information about bafetinib, readers can read the media release from CytRx Corp. There seems to be no listing of this trial on the ClinicalTrials.gov web site at the present time.
Filed under: Drugs in development | Tagged: bafetinib, castration-resistant, CRPC |
Leave a Reply